Brett Zbar discusses recent surge in biopharma M&A activity

4 articles · Updated · Bloomberg · Apr 24

General Atlantic’s Brett Zbar, speaking from New York, analyzes the heightened merger and acquisition activity in the biotech sector during a notably busy period.
Zbar highlights increased investor interest and strategic moves by biopharma companies seeking growth and innovation through consolidation.
The discussion comes amid broader industry scrutiny, including concerns about conflicts of interest, as investment activity intensifies across the sector.

Is 2026's biotech M&A boom fueling real innovation or just creating bigger drug monopolies?

How is AI changing the game for biotech M&A valuations and drug discovery timelines?

As China's biotech licensing deals surge, what does it mean for U.S. drug development?

With a $1.2 trillion war chest, which pharma giant will make the next blockbuster acquisition?

How will the BIOSECURE Act reshape the future of US-China biotech collaborations?

Will the looming 'patent cliff' force even disciplined pharma companies into risky acquisitions?